소아의 난치성 간질에서 Vigabatrin의 임상 효과

The clinical Effect of Vigabatrin in Refractory Pediatric Epilepsies

The antiepileptic effect of vigabatrin in the children with refractory epilepsies has been investigated only to a limited extent. In order to assess the efficacy and safety of vigabatrin, 44 children with refractory epilepsies have been treated with vigabatrin in open, add-on studies. The mean duration of the administration was 9 months, and the mean dosage was 73.6mg/kg/day. The results were as follows; seizure free in 18.2% of the cases, 50-90% frequency reduction in 29.5%, and <50% frequency reduction or no change in 52.3%. The efficacy of vigabatrin was rated as 47.7%. The adverse effects were observed in 5 cases which were drowsiness, dizziness, diplopia and nausea. In all cases, however, the administration of vigabatrin could be continued.